Cell Based Immunotherapy Market By Cell Source (Autologous, Allogeneic); By Cell Type (CAR-T Cells, TCR-T Cells, CAR-NK Cells, Tumor-Infiltrating Lymphocytes (TIL)); By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Other Indications); By End User (Hospitals, Specialty Cancer Centers, Academic & Research Institutes); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
The global Cell Based Immunotherapy Market size was estimated at USD 4,953 million in 2025 and is expected to reach USD 12,114.69 million by 2032, growing at a CAGR of 13.63% from 2025 to 2032. Cell Based Immunotherapy Market expansion is being propelled by rising clinical adoption of engineered cell therapies in hematologic oncology, supported by deeper physician familiarity, broader treatment-center readiness, and increasingly standardized care pathways for patient selection and adverse-event management. North America continues to set the pace for commercialization and treatment capacity, and Asia Pacific is advancing quickly as manufacturing capabilities and trial activity expand across major healthcare systems.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Cell Based Immunotherapy Market Size 2025
USD 4,953 million
Cell Based Immunotherapy Market, CAGR
13.63%
Cell Based Immunotherapy Market Size 2032
USD 12,114.69 million
Key Market Trends & Insights
The Cell Based Immunotherapy Market is projected to rise from USD 4,953 million (2025) to USD 12,114.69 million (2032) at 13.63% CAGR (2025–2032).
Autologous therapies accounted for the largest share of 68.90% in 2025, reflecting strong clinical maturity and established treatment workflows.
CAR-T Cells represented 60.85% of 2025 revenue, supported by expanding clinical utilization in oncology centers.
Hospitals held 66.80% share in 2025, driven by intensive monitoring capability and multidisciplinary infrastructure requirements.
North America contributed 39.75% of 2025 revenue, while Asia Pacific is positioned for faster expansion over the coming years due to rising manufacturing capacity, growing clinical trial activity, and improving treatment-center readiness.
Segment Analysis
Cell Based Immunotherapy Market demand is shaped by high clinical value in refractory cancers and by the increasing number of specialized centers able to deliver complex cell therapies. Patient-specific workflows, chain-of-custody requirements, and intensive monitoring needs continue to concentrate utilization in high-capability hospital settings. Pricing intensity and payer scrutiny are influencing contracting structures, site selection, and patient referral networks. At the same time, innovation across cell engineering and manufacturing is widening the therapy landscape beyond early hematologic indications.
Cell Based Immunotherapy Market segmentation reflects an ongoing shift from purely patient-derived treatment models toward scalable platforms that can reduce lead times and broaden access. Programs focused on off-the-shelf approaches are accelerating as developers improve persistence, safety, and tumor-targeting performance. Cell Based Immunotherapy Market adoption is also supported by rising clinical experience with toxicity management and by improving operational playbooks across apheresis, conditioning regimens, and post-infusion monitoring.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Autologous accounted for the largest share of 68.90% in 2025. Autologous dominance is supported by established clinical protocols, wider physician confidence, and deeper commercial availability across major oncology centers. Autologous products also benefit from clearer patient selection pathways and more standardized delivery models in mature markets. Allogeneic development is gaining traction as next-generation platforms target shorter production timelines and broader patient reach.
By Cell Type Insights
CAR-T Cells accounted for the largest share of 60.85% in 2025. CAR-T leadership is reinforced by multiple commercial programs, expanding treatment experience, and strengthening delivery infrastructure across specialized centers. CAR-T cell therapy also benefits from improving manufacturing throughput and more refined toxicity management pathways. CAR-NK Cells, TCR-T Cells, and Tumor-Infiltrating Lymphocytes (TIL) are progressing as solid-tumor strategies and engineering approaches mature.
By Primary Indication Insights
B-cell Malignancies accounted for the largest share of 41.90% in 2025. B-cell malignancies lead due to strong clinical precedent, validated target biology, and higher concentration of certified centers for hematologic oncology delivery. Reimbursement pathways and treatment-center readiness are typically more mature for hematologic indications than for many solid tumors. Renal Cell Carcinoma, Prostate Cancer, and Liver Cancer are advancing as trial pipelines expand and as combination approaches improve response durability.
By End User Insights
Hospitals accounted for the largest share of 66.80% in 2025. Hospital leadership reflects ICU access, apheresis capability, and the need for multidisciplinary management of complex adverse events. Hospital systems also tend to be earlier adopters due to stronger staffing depth and established cellular therapy units. Specialty Cancer Centers are expanding rapidly as patient volumes rise and as care pathways become more standardized outside large academic hospitals.
Cell Based Immunotherapy Market Drivers
Expanding Oncology Use Cases And Clinical Adoption
Cell Based Immunotherapy Market growth is driven by expanding clinical adoption of engineered cell therapies across oncology care pathways. Treatment centers are increasing cellular therapy capacity through dedicated units, specialized staff, and standardized adverse-event management protocols. Clinical confidence is improving as real-world experience grows across patient selection, bridging strategies, and post-infusion monitoring. Cell Based Immunotherapy Market demand is also supported by expanding trial pipelines that widen the addressable population across multiple tumor types.
Improving Manufacturing Capacity And Supply Reliability
Cell Based Immunotherapy Market momentum is strengthened by manufacturing scale-up and improving supply reliability across commercial programs. Developers are expanding production networks, qualifying additional sites, and improving chain-of-identity controls to reduce operational risk. Process improvements in vector supply, cell expansion, and quality testing are helping shorten cycle times and increase batch consistency. Cell Based Immunotherapy Market commercialization benefits when capacity expansion reduces patient wait times and increases treatment throughput.
Technology Advances In Cell Engineering And Target Discovery
Cell Based Immunotherapy Market expansion is supported by advances in cell engineering, target discovery, and next-generation construct design. Innovations such as improved co-stimulatory designs, better persistence strategies, and refined antigen selection are helping address efficacy and durability goals. Solid-tumor development is advancing through improved trafficking, tumor microenvironment navigation, and combination strategies. Cell Based Immunotherapy Market growth accelerates as these advances improve response rates and reduce safety trade-offs.
For instance, Allogene reported that its gene-edited allogeneic CD19 CAR-T program cema-cel/ALLO-501 achieved a 67% overall response rate and a 58% complete response rate with the selected Phase II regimen in relapsed or refractory large B-cell lymphoma, while the median duration of response reached 23.1 months, underscoring progress in next-generation cell engineering and durability optimization.
Increasing Investment And Ecosystem Maturity
Cell Based Immunotherapy Market development is fueled by sustained investment across biopharma pipelines, CDMO capacity, and hospital readiness programs. Strategic partnerships and licensing activity are increasing access to platforms, vectors, and manufacturing capability. Training programs and standardized center accreditation models are improving consistency across patient pathways. Cell Based Immunotherapy Market adoption rises when ecosystem maturity lowers operational friction for new treatment centers.
For instance, Legend Biotech reported in March 2026 that CARVYKTI was available in 14 markets across 294 sites worldwide, that more than 10,000 clinical and commercial patients had been treated to date, and that the expanded Raritan manufacturing facility can support treatment of up to 10,000 patients annually, reflecting a more mature commercial and treatment-center ecosystem.
Cell Based Immunotherapy Market Challenges
Cell Based Immunotherapy Market expansion faces challenges from complex manufacturing workflows and supply constraints for patient-specific products. Treatment timelines can be impacted by capacity limits, logistics coordination, and variability in starting material quality. High operational complexity increases the burden on treatment centers and can restrict broader geographic rollout. Cell Based Immunotherapy Market cost intensity also drives payer scrutiny and tighter utilization management frameworks.
Cell Based Immunotherapy Market growth is also constrained by clinical safety risks and variability in patient outcomes across heterogeneous populations. Cytokine-related toxicities and neurologic adverse events require experienced clinical teams and strong inpatient monitoring capability. Limited access to accredited centers can create geographic disparities and referral bottlenecks. Cell Based Immunotherapy Market penetration improves when safety management becomes more standardized and when delivery expands beyond a small number of high-volume sites.
For instance, in the pivotal ELIANA trial and subsequent real-world evidence, Kymriah demonstrated any-grade cytokine release syndrome (CRS) in 77% of treated pediatric B-ALL patients and grade ≥3 CRS in 48%, while any-grade neurologic events occurred in 40% (grade ≥3 in 13%). management protocols now mandate certified centers with ICU backup
Cell Based Immunotherapy Market Trends and Opportunities
Cell Based Immunotherapy Market innovation is shifting toward off-the-shelf platforms that can reduce lead times and broaden access. Allogeneic approaches, including engineered NK and T-cell platforms, are being developed to improve scalability and enable inventory-based distribution. Development programs are also focusing on better persistence and improved safety through refined engineering strategies. Cell Based Immunotherapy Market opportunity increases when scalable models reduce the operational burden on treatment centers.
For instance, Allogene Therapeutics’ cema-cel (ALLO-501) demonstrated in the Phase I UNIVERSAL trial that approximately 90% of patients received allogeneic CAR-T cells within 5 days of enrollment, representing a 4- to 6-week reduction compared to autologous manufacturing timelines, while enabling production of approximately 100 doses from a single manufacturing run.
Cell Based Immunotherapy Market opportunity is also expanding through solid-tumor progress and broader modality diversification. Tumor-Infiltrating Lymphocytes (TIL) and TCR-T pipelines are gaining attention as developers improve antigen selection and address tumor microenvironment barriers. Combination approaches with checkpoint inhibitors and targeted agents are becoming more common in clinical strategies. Cell Based Immunotherapy Market growth benefits when new indications expand the eligible population beyond hematologic cancers.
Regional Insights
North America
Cell Based Immunotherapy Market revenue in North America accounted for 39.75% in 2025, supported by strong reimbursement structures, higher center density, and established commercialization networks. The region benefits from deep clinical trial activity and high concentration of specialized oncology institutions. Manufacturing networks and distribution capability are generally more mature across the United States and Canada. North America remains the reference market for early adoption of next-generation programs.
Europe
Cell Based Immunotherapy Market revenue in Europe is estimated at 27.10% in 2025, supported by advanced oncology infrastructure in key Western European markets. Treatment capacity is rising as more hospitals develop accredited cell therapy units and expand staff training. Reimbursement and access conditions vary by country, which shapes uneven adoption across the region. Europe continues to expand as cross-border experience and standardized delivery pathways improve.
Asia Pacific
Cell Based Immunotherapy Market revenue in Asia Pacific is estimated at 23.60% in 2025, with rapid expansion supported by rising trial participation and increasing investment in advanced therapy manufacturing. Major economies are scaling treatment-center capability and strengthening clinical protocols for complex cell therapies. Access and reimbursement conditions remain uneven across countries, which impacts near-term penetration. Asia Pacific is positioned for faster growth as capacity expansion continues.
Latin America
Cell Based Immunotherapy Market revenue in Latin America is estimated at 5.85% in 2025, reflecting early-stage adoption concentrated in leading private and academic centers. Limited certified center coverage and constrained reimbursement pathways reduce broad access for high-cost therapies. Referral networks are developing, but patient volumes remain concentrated in a small number of major cities. Latin America opportunity increases as clinical infrastructure and payer models mature.
Middle East & Africa
Cell Based Immunotherapy Market revenue in Middle East & Africa is estimated at 3.70% in 2025, driven mainly by emerging capability hubs in select countries. Limited availability of specialized centers and variable coverage policies restrict wider adoption. Cross-border treatment travel remains a relevant pathway for complex cases in many markets. Middle East & Africa growth improves as investment increases in accredited centers and local manufacturing partnerships.
Competitive Landscape
Cell Based Immunotherapy Market competition is characterized by rapid innovation cycles, expanding manufacturing footprints, and active lifecycle management across approved cell therapy franchises. Leading players differentiate through deeper clinical evidence, broader indication strategies, and operational scale that supports reliable product supply. Partnerships with manufacturing specialists and regional expansion strategies are common as companies seek to improve capacity and reduce delivery friction. Pipeline breadth across CAR-T, TCR-T, CAR-NK, and TIL modalities is a key lever for long-term positioning.
Novartis AG maintains a strong footprint through continued development of engineered cell therapy capabilities and manufacturing readiness across key markets. Novartis AG strategic focus includes capacity reliability, clinical evidence expansion, and operational execution to support treatment-center throughput. Novartis AG also benefits from established relationships with leading oncology institutions and experience supporting complex cellular therapy workflows. This positioning supports resilience as competition increases across next-generation modalities.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In February 2026, Gilead Sciences announced its agreement to acquire Arcellx in a landmark $7.8 billion transaction to maximize the long-term potential of anito-cel (anitocabtagene autoleucel), a next-generation BCMA-directed CAR-T cell therapy for relapsed or refractory multiple myeloma.
In October 2025, Avantor partnered with BlueWhale Bio to accelerate CAR-T manufacturing by addressing critical production bottlenecks, reducing variability, and shortening time-to-patient for immune cell therapies. This collaboration leverages BlueWhale’s Synecta™ cell-derived extracellular vesicle platform and Avantor’s mission-critical products and services to transform the manufacturing landscape for cell-based immunotherapies.
In September 2025, Kytopen announced a collaboration with BlueWhale Bio to develop a non-viral manufacturing workflow that eliminates current bottlenecks in cell therapy production, potentially giving patients faster access to more effective, personalized treatments. This partnership aims to revolutionize cell therapy manufacturing by combining Kytopen’s continuous flow cellular engineering technologies with BlueWhale’s innovative manufacturing platform
Report Scope
Report Attribute
Details
Market size value in 2025
USD 4,953 million
Revenue forecast in 2032
USD 12,114.69 million
Growth rate (CAGR)
13.63% (2025–2032)
Base year
2025
Forecast period
2026–2032
Quantitative units
USD million
Segments covered
By Cell Source Outlook: Autologous, Allogeneic | By Cell Type Outlook: CAR-T Cells, TCR-T Cells, CAR-NK Cells, Tumor-Infiltrating Lymphocytes (TIL) | By Primary Indication Outlook: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Other Indications | By End User Outlook: Hospitals, Specialty Cancer Centers, Academic & Research Institutes
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
1. Introduction
1.1 Report Description
1.2 Purpose of the Report
1.3 USP & Key Offerings
1.4 Key Benefits for Stakeholders
1.5 Target Audience
1.6 Report Scope
1.7 Regional Scope 2. Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology 3. Executive Summary 4. Market Overview
4.1 Overview
4.2 Key Industry Trends 5. Global Cell Based Immunotherapy Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast 6. Market Breakup by Cell Source
6.1 Autologous
6.2 Allogeneic 7. Market Breakup by Cell Type
7.1 CAR-T Cells
7.2 TCR-T Cells
7.3 CAR-NK Cells
7.4 Tumor-Infiltrating Lymphocytes (TIL) 8. Market Breakup by Primary Indication
8.1 B-cell Malignancies
8.2 Prostate Cancer
8.3 Renal Cell Carcinoma
8.4 Liver Cancer
8.5 Other Indications 9. Market Breakup by End User
9.1 Hospitals
9.2 Specialty Cancer Centers
9.3 Academic & Research Institutes 10. Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Asia-Pacific
10.2.1 China
10.2.2 Japan
10.2.3 India
10.2.4 South Korea
10.2.5 Australia
10.2.6 Indonesia
10.2.7 Others
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 United Kingdom
10.3.4 Italy
10.3.5 Spain
10.3.6 Russia
10.3.7 Others
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Others
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast 11. SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats 12. Value Chain Analysis 13. Porter’s Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes 14. Price Analysis 15. Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Novartis AG
15.3.2 Gilead Sciences
15.3.3 Bristol-Myers Squibb
15.3.4 Johnson & Johnson
15.3.5 Legend Biotech
15.3.6 Allogene Therapeutics
15.3.7 bluebird bio
15.3.8 Fate Therapeutics
15.3.9 Adaptimmune Therapeutics
15.3.10 Takeda Pharmaceutical
15.3.11 Atara Biotherapeutics
15.3.12 Autolus Limited
15.3.13 Cellectis
15.3.14 Iovance Biotherapeutics 16. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size of the Cell Based Immunotherapy Market?
The Cell Based Immunotherapy Market was valued at USD 4,953 million in 2025. Cell Based Immunotherapy Market sizing reflects commercial adoption across major oncology centers.
What is the forecast value and growth rate for the Cell Based Immunotherapy Market?
The Cell Based Immunotherapy Market is expected to reach USD 12,114.69 million by 2032. The Cell Based Immunotherapy Market is projected to grow at a 13.63% CAGR from 2025 to 2032.
Which segment is largest in the Cell Based Immunotherapy Market?
CAR-T Cells represent the largest cell type with 60.85% share in 2025. CAR-T leadership is driven by established clinical workflows and expanding treatment capacity.
What factors are driving growth in the Cell Based Immunotherapy Market?
Cell Based Immunotherapy Market growth is driven by increasing clinical adoption in oncology and by expanding treatment-center readiness. Manufacturing scale-up and advancing cell engineering also strengthen market expansion.
Who are the leading companies in the Cell Based Immunotherapy Market?
Key companies include Novartis AG, Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, and Legend Biotech. Additional important participants include Allogene Therapeutics, Iovance Biotherapeutics, and Autolus Limited.
Which region leads the Cell Based Immunotherapy Market?
North America leads with 39.75% share in 2025. North America leadership is supported by higher treatment-center density and stronger reimbursement maturity.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Cardiac Arrhythmia Therapeutics Market size was estimated at USD 7478 million in 2025 and is expected to reach USD 11658.96 million by 2032, growing at a CAGR of 6.55% from 2025 to 2032.
The global Capecitabine Market size was estimated at USD 1177 million in 2025 and is expected to reach USD 1689.45 million by 2032, growing at a CAGR of 5.3% from 2025 to 2032.
The global Calcineurin Inhibitors Market size was estimated at USD 12,740 million in 2025 and is expected to reach USD 23,289.07 million by 2032, growing at a CAGR of 9% from 2025 to 2032.
The global Cancer Diagnostic Market size was estimated at USD 116,108 million in 2025 and is expected to reach USD 173,893.11 million by 2032, growing at a CAGR of 5.94% from 2025 to 2032.
The global Cancer Cachexia Market size was estimated at USD 2,836 million in 2025 and is expected to reach USD 4,125.24 million by 2032, growing at a CAGR of 5.5% from 2025 to 2032.
The global Cancer Biomarkers Market size was estimated at USD 38349 million in 2025 and is expected to reach USD 87462.46 million by 2032, growing at a CAGR of 12.5% from 2025 to 2032.
The global Calcifediol Supplements Market size was estimated at USD 1,398 million in 2025 and is expected to reach USD 2,557.24 million by 2032, growing at a CAGR of 9.01% from 2025 to 2032.
The global Buprenorphine and Naloxone Market size was estimated at USD 4,918 million in 2025 and is expected to reach USD 6,484.83 million by 2032, growing at a CAGR of 4.03% from 2025 to 2032.
The Irritable Bowel Syndrome with Constipation Drugs Market size was valued at USD 4,130 million in 2024 and is anticipated to reach USD 7,814.93 million by 2032, growing at a CAGR of 8.3% during the forecast period.
The Adalimumab Drugs Market is projected to grow from USD 14,947.5 million in 2025 to an estimated USD 21,229.73 million by 2032, with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
The Global Acute Myeloid Leukemia (AML) Therapeutics Market size was valued at USD 1,933.8 million in 2018 to USD 3,349.2 million in 2024 and is anticipated to reach USD 6,823.4 million by 2032, at a CAGR of 9.33% during the forecast period
The Argatroban Market is projected to grow from USD 684.95 Million in 2024 to an estimated USD 911.10 Million by 2032, with a CAGR of 4.87% from 2024 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
